Bioequivalence Studies of Two Fixed‐Dose Combination of Dapagliflozin and Metformin XR Formulations in Healthy Participants Under Fed and Fasting Conditions
Clinical Pharmacology in Drug Development · 2026-11 · 15 (11)
DOI: 10.1002/cpdd.70129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 20.11.2026. Verfasst von Gökçe Sözer und 3 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In order to assess the bioequivalence of two fixed‐dose combination extended‐release film‐coated tablets containing 10 mg dapagliflozin and 1000 mg metformin hydrochloride under fed and fasting conditions, two trials were conducted. Participants received a single oral dose of either the test or reference product, followed by the alternate formulation in the subsequent period. Area under the plasma concentration–time curve (AUC 0–tlast and AUC 0–∞ ), maximum plasma concentration (C max ), and time to reach C max (t max ) were compared. Under fasting conditions, AUC 0–tlast , AUC 0–∞ , and C max for dapagliflozin were 337.132 ng h/mL, 366.857 ng h/mL, and 96.593 ng/mL, respectively, for the test product and 321.907 ng h/mL, 340.694 ng h/mL, and 101.323 ng/mL for the reference product. For metformin, corresponding values were 7237.400 ng h/mL, 7556.136 ng h/mL, and 1082.023 ng/mL for the test, and 7009.890 ng h/mL, 7290.756 ng h/mL, and 1055.115 ng/mL for the reference. When administered with food, dapagliflozin showed similar exposure but a slightly lower C max , while metformin reached a similar C max at a slightly later t max with higher AUC values. The 90% CIs for AUC 0–tlast , AUC 0–∞ , and C max for both analytes fell under both conditions within the bioequivalence acceptance range. Products were found to be bioequivalent. No clinically meaningful differences in safety or tolerability were observed.
Zitieren
APA
Sözer, G., Abdulkhaleq, A., Zead, I., & Zeidan, R. (2026). Bioequivalence Studies of Two Fixed‐Dose Combination of Dapagliflozin and Metformin XR Formulations in Healthy Participants Under Fed and Fasting Conditions. Clinical Pharmacology in Drug Development, 15(11). https://doi.org/10.1002/cpdd.70129
Vancouver
Sözer G, Abdulkhaleq A, Zead I, Zeidan R. Bioequivalence Studies of Two Fixed‐Dose Combination of Dapagliflozin and Metformin XR Formulations in Healthy Participants Under Fed and Fasting Conditions. Clinical Pharmacology in Drug Development. 2026;15(11). doi:10.1002/cpdd.70129
BibTeX
@article{Szer2026,
author = {Sözer, Gökçe and Abdulkhaleq, Ahmad and Zead, Iyad and Zeidan, Rana},
title = {Bioequivalence Studies of Two Fixed‐Dose Combination of Dapagliflozin and Metformin XR Formulations in Healthy Participants Under Fed and Fasting Conditions},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cpdd.70129}
}
EUVIMED